A Study to Assess Adverse Events, How the Drug Moves Through the Body and Effectiveness of Intravenous Infusions of ABBV-319 in Adult Participants With Systemic Lupus Erythematosus (SLE) and Sjogren's Disease (SjD)

NCT06977724 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

36

Enrollment

INDUSTRY

Sponsor class

Conditions

Dry Eye Syndrome
Systemic Lupus Erythematosus

Interventions

DRUG: ABBV-319

Sponsor

AbbVie